Circassia’s grass allergy treatment is a novel mixture of synthetic peptide immuno-regulatory epitopes identified using our ToleroMune® technology.
Grass allergy, the most common cause of hay fever, is extremely prevalent. In Europe and the United States approximately 17 – 27% of the population are sensitized to pollen from different grass species. Grass allergy is a seasonal condition, and can debilitate sufferers during the months when pollen is released, resulting in significant healthcare costs, workplace / school absences and the inability to spend time outdoors.
Grass allergy treatment
Circassia’s grass allergy treatment incorporates synthetically produced peptides identified from the allergens from key grass varieties. In a phase IIb trial conducted in Canada, subjects in the optimal treatment group had a significant reduction in allergy symptoms (p=0.035) at the end of the first grass pollen season. The symptom improvement was sustained over two further grass pollen seasons when measured in subjects returning each season, despite no additional doses. Following these encouraging results, Circassia began a registration field study in H1 2016. However, following surprising and disappointing phase III results with Circassia’s cat allergy treatment the grass allergy immunotherapy study has been stopped. Consequently, Circassia will now await the results from its large house dust mite allergy field study to inform the approach to its wider allergy portfolio.
Pipeline status: Grass allergy
Registration Study /